Authors: Bice, WS Prestidge, BR Sarosdy, MF

Citation: Ws. Bice et al., Calibration, calculation, and prescription issues in permanent prostate brachytherapy with (PD)-P-103, INT J RAD O, 49(1), 2001, pp. 289-291

Authors: Sarosdy, MF Schellhammer, PF Johnson, R Carroll, K Kolvenbag, GJCM

Citation: Mf. Sarosdy et al., Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?, UROLOGY, 55(3), 2000, pp. 391-395

Authors: Lamm, DL Blumenstein, BA Crissman, JD Montie, JE Gottesman, JE Lowe, BA Sarosdy, MF Bohl, RD Grossman, HB Beck, TM Leimert, JT Crawford, ED

Citation: Dl. Lamm et al., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study, J UROL, 163(4), 2000, pp. 1124-1129

Authors: Sarosdy, MF Schellhammer, PF Soloway, MS Vogelzang, NJ Crawford, ED Presti, J Chodak, GW Mitchell, P Porter, L

Citation: Mf. Sarosdy et al., Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer, BJU INT, 83(7), 1999, pp. 801-806

Authors: Sarosdy, MF

Citation: Mf. Sarosdy, Which is the optimal antiandrogen for use in combined androgen blockade ofadvanced prostate cancer? The transition from a first- to second-generation antiandrogen, ANTI-CANC D, 10(9), 1999, pp. 791-796

Authors: McLeod, DG Schellhammer, PF Vogelzang, NJ Soloway, MS Sharifi, R Block, NL Venner, PM Patterson, AL Sarosdy, MF Kelley, RP Kolvenbag, GJCM

Citation: Dg. Mcleod et al., Exploratory analysis on the effect of race on clinical outcome in patientswith advanced prostate cancer receiving bicalutamide or flutamide, each incombination with LHRH analogues, PROSTATE, 40(4), 1999, pp. 218-224